New Growth Models In China: McKinsey-PharmAsia Summit Report Preview
This article was originally published in The Pink Sheet Daily
Executive Summary
With increased pricing pressure on branded generics, MNCs in China need to fundamentally redesign their business models with stronger market-access capabilities and to shift resources away from brands under acute pressure to support those with bigger future potential, according to a survey conducted by McKinsey & Company.